Milestone Achievement for Chimeric Therapeutics

Chimeric Therapeutics (ASX: $CHM) has achieved a significant milestone by enrolling the first participant in the Phase 1/2 multi-centre clinical trial for CHM CDH17 cell therapy. The trial, designated as NCT06055439, aims to determine the recommended Phase 2 dose of CHM CDH17 and assess its safety and objective response rate in patients with advanced colorectal cancer, gastric cancer, and intestinal neuroendocrine tumours.

Executive Commentary on Milestone Achievement

This is great progress for this first-in-human study for bowel cancer patients with significant unmet need; congratulations to the CHM team and our investigational sites on this milestone.

Summary of CHM CDH17 Phase 1/2 Trial

Chimeric Therapeutics has successfully enrolled the first participant in the Phase 1/2 multi-centre clinical trial for CHM CDH17 cell therapy, marking a significant advancement in the development of innovative cell therapies for cancer treatment. The company's focus on bringing the promise of cell therapy to life for more cancer patients is evident through its diversified portfolio, including first in class autologous CAR T cell therapies and best in class allogeneic NK cell therapies. With additional clinical trial sites anticipated to open in the second half of 2024, Chimeric Therapeutics is poised to further expand its clinical programs and continue its pursuit of developing new next generation NK and CAR NK assets.